Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 125-133

  Derendorf, Hartmut ^a   Munzel, Ullrich ^b   Petzold, Ursula ^b   Maus, Joachim ^b   Mascher, Hermann ^c   Hermann, Robert ^d   Bousquet, Jean ^e,f  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b MEDA Pharma GmbH and Co KG   (Germany)

^c Pharm analyt Labor GmbH   (Austria)

^d Crappliance ^*  (Germany)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f INSERM   (France)

Author keywords

Azelastine hydrochloride; Bioavailability; Drug drug interaction; Fluticasone propionate; Nasal spray; Pharmacokinetics

Indexed keywords

AZELASTINE; FLUTICASONE PROPIONATE; MP 29 02; NOSE SPRAY; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84862137976     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04222.x     Document Type: Article

References (23)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C etal. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8-160.
2. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-76.
3. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA, Joint Task Force on Practice, American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122 (Suppl.): S1-84.
4. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999; 103: S388-94.
5. Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, Zuberbier T. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124: 428-33.
6. Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100: 74-81.
7. Bachert C, Hampel F, Sacks H, Maus J, Munzel U, Price D, Bousquet J. MP29-02 and time to response in the treatment of seasonal allergic rhinitis compared to marketed antihistamine and corticosteroid nasal sprays. Allergy 2011; 66 (Suppl. s94): 285.
8. Bachert C, Carr W, Sacks H, Munzel U, Maus J, Price D, Bousquet J. Time to response and onset of action of MP29-02 in the symptomatic treatment of seasonal allergic rhinitis. Allergy 2011; 66 (Suppl. s94): 919.
9. Carr W, Bernstein J, Sacks H, Price D, Bachert C, Bousquet J. MP29-02 in the symptomatic treatment of seasonal allergic rhinitis - a comparative fall study. Allergy 2011; 66 (Suppl. s94): 920.
10. Meltzer E, Carr W, Sacks H, Price D, Bachert C, Bousquet J. MP29-02 in the symptomatic treatment of seasonal allergic rhinitis - a comparative spring study. Allergy 2011; 66 (Suppl. s94): 286.
11. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Development of Fixed Combination Medicinal Products. CHMP/EWP/240/95 Rev. 1; 19 February 2009.
12. Hermann R, Locher M, Siebert-Weigel M, LaVallee N, Derendorf H, Hochhaus G. Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. J Clin Pharmacol 2004; 44: 510-9.
13. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol 2001; 51: 103-5.
14. Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004; 60: 265-8.
15. Riethmueller-Winzen H, Peter G, Buker KM, Romeis P, Borbe HO. Tolerability, pharmacokinetics and dose linearity of azelastine hydrochloride in healthy subjects. Arzneimittel-Forschung/Drug Research 1994; 44: 1136-40.
16. Callejas S, Biddlecombe R, Jones A, Joyce K, Pereira A, Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr 1998; 718: 243-50.
17. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. CPMP/QWP/EWP/1401/98 Rev. 1; 20 January 2010.
18. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539-42.
19. Meltzer EO, Orgel HA, Bronsky EH, Furukawa CT, Grossman J, LaForce CF, Lemanske RF Jr, Paull BD, Pearlman DS, Ratner PH, Spector SL, Tinkelman DG, van As A, Rogenes PR. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990; 86: 221-30.
20. Van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 1991; 67: 156-62.
21. Nathan RA, Bronsky EA, Fireman P, Grossman J, LaForce CF, Lemanske RF Jr, Pearlman DS, Ratner PH, Rogenes PR. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67: 332-8.
22. Mackie AE, Bye A. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. Clin Pharmacokinet 2000; 39 (Suppl. 1): 47-54.
23. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010; 105: 168-73.